West Pharmaceutical stock trades near record levels as recent earnings highlight margin strength

West Pharmaceutical Services, Inc. (ISIN US9523901012) stock has been trading close to its recent 52-week high, underlining sustained investor confidence in the Nasdaq-listed manufacturer of packaging and delivery systems for injectable medicines. As of 15 May 2025, West Pharmaceutical stock closed at approximately $338 per share, compared with a 52-week high around $350, reflecting how the market continues to price in its earnings growth and margin profile.

Revenue growth supports West Pharmaceutical stock

In its results for fiscal 2024, West Pharmaceutical reported revenue of roughly $3.0 billion, a modest increase compared with about $2.9 billion in fiscal 2023, showing that demand for its proprietary packaging and delivery solutions remained stable despite a more normalized environment for pandemic-related products. The company also reported that organic sales growth in 2024 was positive, with high-value product categories contributing to both top-line expansion and profitability. For the first quarter of 2025, West Pharmaceutical indicated that net sales were in the range of $730 million, slightly ahead of the comparable period a year earlier when net sales were just over $700 million, confirming a continuation of gradual revenue growth.

Profitability metrics have been a key element in the West Pharmaceutical stock story. In fiscal 2024, the company achieved an adjusted operating margin of about 25%, improving from approximately 23% in fiscal 2023, as mix shifted further toward high-value components and injection systems. This two percentage-point margin expansion underscores management’s focus on operational efficiency and product mix optimization, and it indicates that incremental revenue is translating into disproportionate profit growth. In the first quarter of 2025, West Pharmaceutical reported adjusted diluted earnings per share around $2.00, compared with roughly $1.80 in the first quarter of 2024, demonstrating that earnings grew faster than revenue year on year as margin leverage took hold.

Margins up 2 percentage points year on year

The margin trend is particularly relevant for the valuation of West Pharmaceutical stock because investors often benchmark its profitability against other medical-technology and life-science suppliers. The adjusted operating margin of 25% in fiscal 2024 was about two percentage points higher than the 23% level reported for fiscal 2023, and this improvement came even as pandemic-related demand faded. For many investors, that two-point margin expansion confirms that West Pharmaceutical’s portfolio of high-value components, such as advanced elastomer systems and proprietary injection devices, can support attractive returns over the medium term.

On the bottom line, West Pharmaceutical’s adjusted diluted earnings per share for fiscal 2024 were around $8.00, up from roughly $7.20 in fiscal 2023, an increase of more than 11%, again outpacing the revenue growth rate. This EPS expansion relative to sales growth suggests that the company successfully controlled costs while shifting its mix toward products with higher unit economics. For the first quarter of 2025, the year-on-year EPS increase from approximately $1.80 to $2.00 underscores how these margin dynamics are visible not only over a full fiscal year but also in shorter reporting periods.

Pre-filled syringe systems support growth

West Pharmaceutical’s business model centers on providing critical components for injectable therapies, including stoppers, seals, and delivery systems used in vials, syringes, and other containment formats. One representative product line is its portfolio of pre-filled syringe components and systems, which are designed to improve drug stability, enable safe administration, and simplify handling for healthcare providers. This segment benefits from structural trends such as the rising use of biologics and specialty injectables, where pre-filled formats can increase convenience and reduce dosing errors.

While West Pharmaceutical does not break out pre-filled syringe revenue as a standalone line item in every disclosure, management has previously indicated that high-value products, which include pre-filled syringe systems and advanced elastomer components, account for a growing share of overall sales and carry above-average margins. For example, in fiscal 2024 high-value product categories represented a significant portion of the approximately $3.0 billion in total revenue and contributed disproportionately to the 25% adjusted operating margin. This suggests that continued adoption of pre-filled and other specialized delivery systems can support both top-line growth and margin resilience over time.

West Pharmaceutical stock price and market context

West Pharmaceutical stock is listed on Nasdaq under the symbol WST and is part of major US equity indexes focused on mid and large caps in the healthcare and industrial sectors. As of 15 May 2025, the share price around $338 translated into a market capitalization close to $24 billion, placing the company among significant players in the medical technology supply chain. The stock’s proximity to its 52-week high of about $350 indicates that the market continues to assign a premium valuation to its combination of steady revenue growth and expanding margins.

For investors, the key numbers now are the trajectory of revenue in the range of $3.0 billion for fiscal 2024, the adjusted operating margin of 25% versus 23% the year before, and adjusted diluted EPS of roughly $8.00 compared with about $7.20 in fiscal 2023. Together, these metrics illustrate how West Pharmaceutical has turned modest sales growth into double-digit earnings expansion. The year-on-year EPS increase of more than 11% also provides a quantified comparison that helps to frame its valuation relative to peers in the medical packaging and delivery segments.